Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology
Francesca Burlo, Serena Pastore, Gabriele Stocco, Paolo Dalla Zuanna, Debora Curci, Tomoyuki Mizuno, Kei Irie, Andrea Taddio, Alberto Tommasini · 2025
Read Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology by Francesca Burlo, Serena Pastore, Gabriele Stocco, Paolo Dalla Zuanna, Debora Curci, Tomoyuki Mizuno, Kei Irie, Andrea Taddio, Alberto Tommasini (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12754995.txt.
Description
A joint drug given every two weeks fails some children, and Francesca Burlo and co-authors argue for trying weekly doses before quitting it, in work from twenty twenty-five. Four children with joint or eye inflammation were reviewed after standard timing failed them. Blood drug handling was modeled for each child.
All four regained control on weekly shots, with no side effects. Fast clearers only crossed the helpful drug level on the weekly plan; slow clearers rose too. The series is tiny, and the authors know it. Still, the lesson is plain: check how fast a child clears the drug before calling the drug a failure.
Catalog record
| CREATOR | Francesca Burlo, Serena Pastore, Gabriele Stocco, Paolo Dalla Zuanna, Debora Curci, Tomoyuki Mizuno, Kei Irie, Andrea Taddio, Alberto Tommasini |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |